JP2016533360A - 皮膚を明るくする化粧組成物及び方法 - Google Patents
皮膚を明るくする化粧組成物及び方法 Download PDFInfo
- Publication number
- JP2016533360A JP2016533360A JP2016522779A JP2016522779A JP2016533360A JP 2016533360 A JP2016533360 A JP 2016533360A JP 2016522779 A JP2016522779 A JP 2016522779A JP 2016522779 A JP2016522779 A JP 2016522779A JP 2016533360 A JP2016533360 A JP 2016533360A
- Authority
- JP
- Japan
- Prior art keywords
- cosmetic composition
- compound
- vitamin
- ricinoleic acid
- ricinoleate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 74
- 239000000203 mixture Substances 0.000 title claims abstract description 74
- 238000000034 method Methods 0.000 title claims description 21
- -1 vitamin B3 compound Chemical class 0.000 claims abstract description 50
- 229960003656 ricinoleic acid Drugs 0.000 claims abstract description 47
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 claims abstract description 46
- 230000000694 effects Effects 0.000 claims abstract description 34
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract description 29
- 238000004020 luminiscence type Methods 0.000 claims abstract description 28
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 108091005804 Peptidases Proteins 0.000 claims abstract description 11
- 239000004365 Protease Substances 0.000 claims abstract description 11
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 11
- 230000000699 topical effect Effects 0.000 claims abstract description 7
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 38
- 150000001875 compounds Chemical class 0.000 claims description 34
- 229930003270 Vitamin B Natural products 0.000 claims description 23
- 235000019156 vitamin B Nutrition 0.000 claims description 23
- 239000011720 vitamin B Substances 0.000 claims description 23
- 229960003966 nicotinamide Drugs 0.000 claims description 17
- 235000005152 nicotinamide Nutrition 0.000 claims description 17
- 239000011570 nicotinamide Substances 0.000 claims description 17
- HDIFHQMREAYYJW-XGXNLDPDSA-N Glyceryl Ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCC(O)CO HDIFHQMREAYYJW-XGXNLDPDSA-N 0.000 claims description 13
- 230000001815 facial effect Effects 0.000 claims description 13
- 229940116338 glyceryl ricinoleate Drugs 0.000 claims description 13
- 239000000839 emulsion Substances 0.000 claims description 8
- 108090000317 Chymotrypsin Proteins 0.000 claims description 7
- IJRHDFLHUATAOS-DPMBMXLASA-M sodium ricinoleate Chemical compound [Na+].CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O IJRHDFLHUATAOS-DPMBMXLASA-M 0.000 claims description 7
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 claims description 6
- XKGDWZQXVZSXAO-ADYSOMBNSA-N Ricinoleic Acid methyl ester Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OC XKGDWZQXVZSXAO-ADYSOMBNSA-N 0.000 claims description 6
- XKGDWZQXVZSXAO-SFHVURJKSA-N Ricinolsaeure-methylester Natural products CCCCCC[C@H](O)CC=CCCCCCCCC(=O)OC XKGDWZQXVZSXAO-SFHVURJKSA-N 0.000 claims description 6
- BEWFIPLBFJGWSR-UHFFFAOYSA-N butyl 12-acetyloxyoctadec-9-enoate Chemical compound CCCCCCC(OC(C)=O)CC=CCCCCCCCC(=O)OCCCC BEWFIPLBFJGWSR-UHFFFAOYSA-N 0.000 claims description 6
- 229960002376 chymotrypsin Drugs 0.000 claims description 6
- 235000001968 nicotinic acid Nutrition 0.000 claims description 6
- 239000011664 nicotinic acid Substances 0.000 claims description 6
- XKGDWZQXVZSXAO-UHFFFAOYSA-N ricinoleic acid methyl ester Natural products CCCCCCC(O)CC=CCCCCCCCC(=O)OC XKGDWZQXVZSXAO-UHFFFAOYSA-N 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 abstract description 19
- 229930003537 Vitamin B3 Natural products 0.000 abstract description 5
- 235000019160 vitamin B3 Nutrition 0.000 abstract description 5
- 239000011708 vitamin B3 Substances 0.000 abstract description 5
- 208000001382 Experimental Melanoma Diseases 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 36
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 17
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 17
- 239000000126 substance Substances 0.000 description 15
- 238000011282 treatment Methods 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 11
- 239000002253 acid Substances 0.000 description 10
- 102000035195 Peptidases Human genes 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- XULHFMYCBKQGEE-UHFFFAOYSA-N 2-hexyl-1-Decanol Chemical compound CCCCCCCCC(CO)CCCCCC XULHFMYCBKQGEE-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 229940066675 ricinoleate Drugs 0.000 description 6
- WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000003995 emulsifying agent Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 208000012641 Pigmentation disease Diseases 0.000 description 4
- 102000003425 Tyrosinase Human genes 0.000 description 4
- 108060008724 Tyrosinase Proteins 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000008406 cosmetic ingredient Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000008099 melanin synthesis Effects 0.000 description 4
- 239000000516 sunscreening agent Substances 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- GEXDKIVVFJCQCK-JCGZMFBFSA-N 2,3-dihydroxypropyl (z,12r)-2-acetyl-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCC(C(C)=O)C(=O)OCC(O)CO GEXDKIVVFJCQCK-JCGZMFBFSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical class C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 3
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- VAKMIIPDYZXBEV-DPMBMXLASA-M potassium;(z,12r)-12-hydroxyoctadec-9-enoate Chemical compound [K+].CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O VAKMIIPDYZXBEV-DPMBMXLASA-M 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- GAWWVVGZMLGEIW-GNNYBVKZSA-L zinc ricinoleate Chemical compound [Zn+2].CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O.CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O GAWWVVGZMLGEIW-GNNYBVKZSA-L 0.000 description 3
- 229940100530 zinc ricinoleate Drugs 0.000 description 3
- CDGSOUOOAKXNKU-RPYYYHSRSA-N (z,12r)-2-acetyl-12-hydroxyoctadec-9-enoic acid Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCC(C(C)=O)C(O)=O CDGSOUOOAKXNKU-RPYYYHSRSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- ZBSGKPYXQINNGF-UHFFFAOYSA-N N-nicotinoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CN=C1 ZBSGKPYXQINNGF-UHFFFAOYSA-N 0.000 description 2
- SUEGNWDYVDUYBZ-YNKKZALPSA-N [2-hydroxy-3-[(Z,12R)-12-hydroxyoctadec-9-enoyl]oxypropyl] (Z,12R)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCC(O)COC(=O)CCCCCCC\C=C/C[C@H](O)CCCCCC SUEGNWDYVDUYBZ-YNKKZALPSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000003212 astringent agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 229940048851 cetyl ricinoleate Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- AZXVZUBIFYQWJK-KWRJMZDGSA-N ethyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCC AZXVZUBIFYQWJK-KWRJMZDGSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- XAMHKORMKJIEFW-AYTKPMRMSA-N hexadecyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC\C=C/C[C@H](O)CCCCCC XAMHKORMKJIEFW-AYTKPMRMSA-N 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003061 melanogenesis Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- ZNSIOEUWGZNHAQ-UHFFFAOYSA-N (3e)-n-diazoniopyridine-3-carboximidate Chemical compound [N-]=[N+]=NC(=O)C1=CC=CN=C1 ZNSIOEUWGZNHAQ-UHFFFAOYSA-N 0.000 description 1
- ZWVMLYRJXORSEP-UHFFFAOYSA-N 1,2,6-Hexanetriol Chemical compound OCCCCC(O)CO ZWVMLYRJXORSEP-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- RIXCYAQOGLLEIU-UINBUCCLSA-N 2,3-bis[[(z,12r)-12-acetyloxyoctadec-9-enoyl]oxy]propyl (z,12r)-12-acetyloxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](OC(C)=O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/C[C@@H](CCCCCC)OC(C)=O)COC(=O)CCCCCCC\C=C/C[C@@H](CCCCCC)OC(C)=O RIXCYAQOGLLEIU-UINBUCCLSA-N 0.000 description 1
- OMERZWZBMKPVFL-DPUWJTKESA-N 2-[(z,12r)-12-hydroxyoctadec-9-enoyl]oxypropyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC\C=C/C[C@H](O)CCCCCC OMERZWZBMKPVFL-DPUWJTKESA-N 0.000 description 1
- XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 description 1
- JZSMZIOJUHECHW-GTJZZHROSA-N 2-hydroxypropyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCC(C)O JZSMZIOJUHECHW-GTJZZHROSA-N 0.000 description 1
- 241001237961 Amanita rubescens Species 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000005058 Isophorone diisocyanate Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 208000009795 Microphthalmos Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- IYCHDNQCHLMLJZ-UHFFFAOYSA-N Nicoxamat Chemical compound ONC(=O)C1=CC=CN=C1 IYCHDNQCHLMLJZ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 102000011420 Phospholipase D Human genes 0.000 description 1
- 108090000553 Phospholipase D Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- GTTSNKDQDACYLV-UHFFFAOYSA-N Trihydroxybutane Chemical compound CCCC(O)(O)O GTTSNKDQDACYLV-UHFFFAOYSA-N 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 108010005705 Ubiquitinated Proteins Proteins 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical class [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000021472 generally recognized as safe Nutrition 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- OQLKNTOKMBVBKV-UHFFFAOYSA-N hexamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 OQLKNTOKMBVBKV-UHFFFAOYSA-N 0.000 description 1
- 229960001915 hexamidine Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- HQRJTRSKPWEIII-OCANKYAHSA-N icosan-9-yl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCC\C=C/C[C@H](O)CCCCCC HQRJTRSKPWEIII-OCANKYAHSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000007934 lip balm Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 201000010478 microphthalmia Diseases 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229960004738 nicotinyl alcohol Drugs 0.000 description 1
- YZUUTMGDONTGTN-UHFFFAOYSA-N nonaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCO YZUUTMGDONTGTN-UHFFFAOYSA-N 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- FJCFFCXMEXZEIM-UHFFFAOYSA-N oxiniacic acid Chemical compound OC(=O)C1=CC=C[N+]([O-])=C1 FJCFFCXMEXZEIM-UHFFFAOYSA-N 0.000 description 1
- SXRAILSODLEVQJ-OLLSULERSA-N oxolan-2-ylmethyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCC1CCCO1 SXRAILSODLEVQJ-OLLSULERSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229940120149 polyglyceryl-3 ricinoleate Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- SDYPTODXHIAHDF-ACQXMXPUSA-N propan-2-yl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OC(C)C SDYPTODXHIAHDF-ACQXMXPUSA-N 0.000 description 1
- BPJZKLBPJBMLQG-KWRJMZDGSA-N propanoyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OC(=O)CC BPJZKLBPJBMLQG-KWRJMZDGSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- ATBIAJXSKNPHEI-UHFFFAOYSA-N pyridine-3-carbonyl chloride Chemical compound ClC(=O)C1=CC=CN=C1 ATBIAJXSKNPHEI-UHFFFAOYSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 102000003702 retinoic acid receptors Human genes 0.000 description 1
- 108090000064 retinoic acid receptors Proteins 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- WWDMJSSVVPXVSV-YCNIQYBTSA-N retinyl ester Chemical compound CC1CCCC(C)(C)C1\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O WWDMJSSVVPXVSV-YCNIQYBTSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000006663 ubiquitin-proteasome pathway Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 150000002266 vitamin A derivatives Chemical class 0.000 description 1
- 150000003697 vitamin B6 derivatives Chemical class 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 102000009310 vitamin D receptors Human genes 0.000 description 1
- 108050000156 vitamin D receptors Proteins 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Cosmetics (AREA)
Abstract
Description
様々な化粧組成物、より具体的には、皮膚表面への塗布用の化粧組成物が提供される。化粧組成物は、ビタミンB3化合物とリシノール酸化合物との組み合わせを含む。化粧組成物は、液剤、懸濁液、ローション、クリーム、ゲル、トナー、スティック、スプレー、エアロゾル、軟膏、クレンジングリキッド洗浄液及び固形バー、ペースト、フォーム、ムース、シェービングクリーム、拭き取り用品、ストリップ、パッチ、電気駆動パッチ、ヒドロゲル、フィルム形成製品、顔面及び皮膚マスク(不溶性シートを伴うもの及び伴わないもの)、ファンデーション、アイライナー及びアイシャドウ等のメークアップ等が挙げられるがこれらに制限されない、様々な製品形態で提供され得る。組成物中に担体が存在する場合、化粧組成物の形態は、選択された特定の皮膚科学的に許容される担体に従い得る。
化粧組成物は、ビタミンB3化合物を含む。本発明で使用するとき、「ビタミンB3化合物」とは、次式:
化粧組成物は、リシノール酸化合物を更に含む。本明細書で使用するとき、「リシノール酸化合物」とは、リシノール酸及びその誘導体を意味する。リシノール酸化合物のいくつかの例としては、アセチル化ラノリンリシノレエート、アセチルリシノール酸グリセリル、アセチルリシノール酸ブチル、アセチルリシノール酸セチル、リシノール酸セチル、リシノール酸安息香酸セチル、ポリリシノール酸エチルヘキシル、リシノール酸エチル、ジリシノール酸グリセリル、ジリシノール酸グリセリル/IPDIコポリマー、リシノール酸グリセリル、リシノール酸グリセリルSE、トリアセチルリシノール酸グリセリル、グリコールリシノレエート、リシノール酸イソプロピル、ラノリンリシノレエート、アセチルリシノール酸メチル、リシノール酸メチル、リシノール酸オクチルドデシル、ジリシノール酸PEG−20、ジ/トリリシノール酸PEG−8、リシノール酸グリセリルPEG−15、リシノール酸グリセリルPEG−20、ジリシノール酸PEG/PPG−10/2、ジリシノール酸PEG/PPG−32/3、リシノール酸PEG/PPG−10/2、リシノール酸PEG/PPG−32/3、リシノール酸PEG−2、リシノール酸PEG−7、リシノール酸PEG−8、リシノール酸PEG−9、リシノール酸フィトステリル、デカエルカ酸/デカイソステアリン酸/デカリシノール酸ポリグリセリル−8、ペンタリシノール酸ポリグリセリル−3、ペンタリシノール酸ポリグリセリル−6、ペンタリシノール酸ポリグリセリル−10、ポリリシノール酸ポリグリセリル−3、ポリリシノール酸ポリグリセリル−4、ポリリシノール酸ポリグリセリル−5、ポリリシノール酸ポリグリセリル−6、ポリリシノール酸ポリグリセリル−10、リシノール酸ポリグリセリル−3、リシノール酸ポリグリセリル−6、ポリラクタート/リシノール酸、ポリオキシプロピレンソルビトールリシノレアート、リシノール酸カリウム、プロピレングリコールジリシノレアート、プロピレングリコールリシノレアート、リシノール酸ナトリウム、リシノール酸スクロース、硫化TEA−リシノール酸、TEA−ジリシノール酸、TEA−ジリシノール酸、リシノール酸テトラヒドロフルフリル、及びリシノール酸亜鉛が挙げられる。リシノール酸化合物のいくつかの好ましい例としては、リシノール酸、リシノール酸エチル、リシノール酸メチル、リシノール酸カリウム、リシノール酸ナトリウム、リシノール酸亜鉛、アセチルリシノール酸、リシノール酸グリセリル、アセチルリシノール酸グリセリルが挙げられるが、これらに制限されない。
ビタミンB3化合物とリシノール酸化合物との組み合わせは、プロテアソームのプロテアーゼ活性を有利にアップレギュレートする、更には相乗的にアップレギュレートすることができると考えられ、これは結果的に、メラニン生成を減らすことができる。図1は、プロテアソームのプロテアーゼ活性経路を図示する。ユビキチン−プロテアソーム系は、多くのタンパク質の廃棄において機能する。ユビキチンは、相対的に小さいポリペプチド(約8000ダルトン)であり、E酵素(E1、E2、E3)によって活性化され、分解されることになっている特定のタンパク質に付着される。次に、ユビキチン化されたタンパク質は、プロテアソーム複合体によって認識され、タンパク分解によって処理される。ユビキチン−プロテアソーム経路によって調整されるケラチノサイトタンパク質は、ビタミンD受容体及びレチノイン酸受容体を含む。メラニン形成細胞では、ユビキチン−プロテアソーム系は、チロシナーゼを分解することによって皮膚色素沈着を調整することが示された。このメラニン形成を調整するモードは、ホスホリパーゼD(phosphlipase)及び特定の脂肪酸により影響を受ける。
化粧組成物は、皮膚科学的に許容可能な担体(「担体」とも呼ばれることができる)を更に含んでもよく、その担体の中に、ビタミンB3化合物及びリシノール酸化合物が組み込まれて、化合物及び任意のその他の成分が皮膚に送達されることを可能にする。担体は、1つ以上の皮膚科学的に許容可能な固体、半固体、又は液体の充填剤、希釈剤、溶剤、増量剤構成成分、物質等を含有し得る。担体は、固体であっても、半固体であっても、液体であってもよい。担体は、多種多様な形態で提供され得る。非限定的な例のいくつかとしては、単純溶液、(水性又は油系)、エマルション、及び固体形態(例えば、ゲル、スティック、流動性固体、無定形物質)が挙げられる。
多種多様な任意の構成成分/成分が、化粧組成物の中に含まれ得る。例えば、化粧組成物は、吸収剤、研磨材、固化防止剤、消泡剤、抗菌剤、結合剤、生物学的添加剤、緩衝剤、充填剤、化学的添加剤、化粧殺生物剤、変性剤、化粧収斂剤、薬物収斂剤、外用鎮痛剤、被膜形成剤、保湿剤、乳白剤、芳香剤、顔料、着色剤、精油、皮膚感覚剤、皮膚軟化剤、皮膚鎮静剤、皮膚回復剤、pH調整剤、可塑剤、防腐剤、防腐増強剤、推進剤、還元剤、追加的スキンコンディショニング剤、皮膚浸透増強剤、皮膚保護剤、溶剤、懸濁化剤、乳化剤、増粘剤、可溶化剤、日焼け止め剤、日焼け防止剤、紫外線吸収剤又は紫外線散乱剤、サンレスタンニング剤、酸化防止剤及び/又はラジカルスカベンジャー、キレート剤、金属イオン封鎖剤、抗ニキビ剤、抗炎症薬、抗アンドロゲン剤、脱毛剤、落屑剤/剥離剤、有機ヒドロキシ酸、ビタミン及びその誘導体、並びに天然抽出物を含み得る。そのような他の物質は、当技術分野では公知である。そのような物質の非排他的な例は、Harry’s Cosmeticology,7th Ed.,Harry & Wilkinson(Hill Publishers,London 1982)、Pharmaceutical Dosage Forms−−Disperse Systems;Lieberman,Rieger & Banker,Vols.1(1988)& 2(1989);Marcel Decker,Inc.、The Chemistry and Manufacture of Cosmetics,2nd.Ed.,deNavarre(Van Nostrand 1962〜1965)、及びThe Handbook of Cosmetic Science and Technology,1st Ed..Knowlton & Pearce(Elsevier 1993)に説明されている。
様々な化粧処置を採用することができる。最も関心のある皮膚表面は、顔面皮膚表面、手及び腕の皮膚表面、足及び脚の皮膚表面、並びに首及び胸の皮膚表面等、一般的に衣服で覆われない皮膚表面である傾向がある。特に、額、口周囲、顎、眼窩周囲、鼻、及び/又は頬の皮膚表面を含む、顔面皮膚表面は、本明細書で説明する化粧組成物で処置され得る。
表5は、ビタミンB3化合物とリシノール酸化合物とを含む粧組成物の、裏付けのない非限定的例を示す。これらの実施例は単に説明のために示すものであり、本発明を限定するものと解釈すべきでなく、本発明の趣旨及び範囲から逸脱することなく多くの改変が可能であり、当業者にはこれらのことが理解されよう。実施例においては、別途記載のない限り、全ての濃度は重量%として掲載されており、希釈剤及び充填剤等の微量の物質は除外され得る。
Claims (15)
- ビタミンB3化合物と、
リシノール酸化合物と、
皮膚科学的に許容可能な担体と、
を含む、皮膚への局所塗布用の化粧組成物。 - 前記ビタミンB3化合物が、ナイアシンアミド、ニコチン酸、ニコン酸メチル、及びニコチンアミドリボースからなる群から選択され、前記ビタミンB3化合物が、前記化粧組成物の1重量%〜10重量%の濃度を有する、請求項1に記載の化粧組成物。
- 前記ビタミンB3化合物が、ナイアシンアミドの誘導体であり、前記誘導体が、ジメチルスルホキシド媒体中のリシノール酸化合物と組み合わせたとき、正味の発光数の計算値の±10%の範囲内である正味の発光数の実測値を有する、請求項1又は2に記載の化粧組成物。
- 前記リシノール酸化合物が、リシノール酸グリセリル、リシノール酸ナトリウム、アセチルリシノール酸ブチル、及びリシノール酸メチルからなる群から選択される、請求項1〜3のいずれか一項に記載の化粧組成物。
- 前記リシノール酸化合物が、前記化粧組成物の1重量%〜10重量%の濃度を有する、請求項1〜4のいずれか一項に記載の化粧組成物。
- 前記ビタミンB3の濃度と前記リシノール酸化合物の濃度との比率が、150:1〜1:2、好ましくは、80:1〜1:2である、請求項1〜5のいずれか一項に記載の化粧組成物。
- 前記皮膚科学的に許容可能な担体が、エマルションの形態である、請求項1〜6のいずれか一項に記載の化粧組成物。
- 前記ビタミンB3化合物が、ナイアシンアミドの誘導体であり、前記誘導体が、ジメチルスルホキシド媒体中のリシノール酸化合物と組み合わせたとき、正味の発光数の計算値より1.3倍以上大きい正味の発光数の実測値を有する、請求項1に記載の化粧組成物。
- 皮膚を明るくすることが望ましい顔の皮膚の標的表面を識別することと、
前記顔の皮膚の標的表面に化粧組成物を塗布することと、
を含み、前記化粧組成物が、ビタミンB3化合物、リシノール酸化合物、及び皮膚科学的に許容可能な担体を含む、顔の皮膚表面を処置するための方法。 - 前記ビタミンB3化合物が、ナイアシンアミド、ニコチン酸、ニコン酸メチル、及びニコチンアミドリボースからなる群から選択され、前記ビタミンB3化合物が、前記化粧組成物の約1重量%〜約10重量%の濃度を有する、請求項9に記載の方法。
- 前記リシノール酸化合物が、リシノール酸グリセリル、リシノール酸ナトリウム、アセチルリシノール酸ブチル、及びリシノール酸メチルからなる群から選択される、請求項9又は10に記載の方法。
- 前記リシノール酸化合物が、前記化粧組成物の1重量%〜10重量%の濃度を有する、請求項9〜11のいずれか一項に記載の方法。
- 前記ビタミンB3化合物の濃度と前記リシノール酸化合物の濃度との比率が、150:1〜1:2、好ましくは、80:1〜1:2である、請求項9〜12のいずれか一項に記載の方法。
- 前記化粧組成物が、プロテアソームのキモトリプシンのプロテアーゼ活性をアプレギュレートするのに十分な期間にわたって、前記顔の皮膚表面に塗布される、請求項9〜13のいずれか一項に記載の方法。
- 前記ビタミンB3化合物が、ナイアシンアミドの誘導体であり、前記誘導体が、ジメチルスルホキシド媒体中のリシノール酸化合物と組み合わせたとき、正味の発光数の計算値より1.3倍以上大きい正味の発光数の実測値を有する、請求項9に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361895271P | 2013-10-24 | 2013-10-24 | |
US61/895,271 | 2013-10-24 | ||
PCT/US2014/061856 WO2015061512A1 (en) | 2013-10-24 | 2014-10-23 | Skin lightening cosmetic compositions and methods |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016533360A true JP2016533360A (ja) | 2016-10-27 |
JP6507158B2 JP6507158B2 (ja) | 2019-04-24 |
Family
ID=51845555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016522779A Active JP6507158B2 (ja) | 2013-10-24 | 2014-10-23 | 皮膚を明るくする化粧組成物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9597271B2 (ja) |
EP (1) | EP3060311B1 (ja) |
JP (1) | JP6507158B2 (ja) |
KR (1) | KR101914844B1 (ja) |
CN (1) | CN105682748B (ja) |
CA (1) | CA2926217C (ja) |
WO (1) | WO2015061512A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018505130A (ja) * | 2016-01-11 | 2018-02-22 | ザ プロクター アンド ギャンブル カンパニー | 皮膚状態を処置する方法及びそのための組成物 |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106715454B (zh) | 2014-07-24 | 2020-06-16 | 格雷斯公司 | 烟酰胺核苷的结晶形式 |
US10189872B2 (en) | 2015-03-09 | 2019-01-29 | W. R. Grace & Co.-Conn | Crystalline form of nicotinamide riboside |
US20160317419A1 (en) * | 2015-05-01 | 2016-11-03 | The Procter & Gamble Company | Method of improving skin health and compositions therefor |
WO2017004102A1 (en) | 2015-06-29 | 2017-01-05 | The Procter & Gamble Company | Multi-component skin care product comprising nicoinamide riboside in a multi-chambered container |
BR112018005742B1 (pt) * | 2015-10-05 | 2021-11-16 | Unilever Ip Holdings B.V. | Composição tópica, método não terapêutico para desinfecção de uma superfície e usos não terapêuticos |
EP3641725A1 (en) | 2017-06-23 | 2020-04-29 | The Procter and Gamble Company | Composition and method for improving the appearance of skin |
EP3727400A4 (en) | 2017-12-22 | 2021-10-20 | Elysium Health, Inc. | CRYSTALLINE FORMS OF NICOTINAMIDE RIBOSIDE CHLORIDE |
WO2019183494A1 (en) | 2018-03-23 | 2019-09-26 | Mary Kay Inc. | Topical compositions and methods |
CN112437657A (zh) | 2018-07-03 | 2021-03-02 | 宝洁公司 | 处理皮肤状况的方法 |
WO2020023690A1 (en) * | 2018-07-25 | 2020-01-30 | International Flavors & Fragrances Inc. | Liquid fragrance compositions |
KR102352050B1 (ko) | 2020-04-22 | 2022-01-17 | 지에스칼텍스 주식회사 | 2,3-부탄다이올을 포함하는 분산제 또는 분산매 조성물, 및 이를 포함하는 화장료 조성물 |
EP4157206A1 (en) | 2020-06-01 | 2023-04-05 | The Procter & Gamble Company | Method of improving penetration of a vitamin b3 compound into skin |
US10959933B1 (en) | 2020-06-01 | 2021-03-30 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
CN112730017B (zh) * | 2021-01-07 | 2024-06-25 | 中国计量大学 | 挥发油复配增溶剂及挥发油酪氨酸酶活性抑制的测定方法 |
WO2024042554A1 (en) * | 2022-08-25 | 2024-02-29 | Istituto Fondazione Di Oncologia Molecolare Ets | A pharmaceutical composition for treatment of viral infections |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002536390A (ja) * | 1999-02-12 | 2002-10-29 | ザ、プロクター、エンド、ギャンブル、カンパニー | ビタミンb3を含有する化粧品組成物 |
US20040102358A1 (en) * | 1997-05-19 | 2004-05-27 | Scivoletto Rosemarie | Composition for treating skin conditions |
JP2009074061A (ja) * | 2001-05-11 | 2009-04-09 | Penreco | ゲル組成物 |
JP2010513368A (ja) * | 2006-12-22 | 2010-04-30 | ユニリーバー・ナームローゼ・ベンノートシヤープ | 化粧品組成物における単結晶板状硫酸バリウム |
JP2011500597A (ja) * | 2007-10-10 | 2011-01-06 | セラメティックス エルエルシー | 皮膚病又は皮膚病変の治療方法及び組成物 |
JP2011140489A (ja) * | 2009-12-18 | 2011-07-21 | L'oreal Sa | まつ毛または眉毛メイクアップ組成物 |
JP2011524393A (ja) * | 2008-06-18 | 2011-09-01 | ユニリーバー・ナームローゼ・ベンノートシヤープ | 皮膚の色を美白するための組成物 |
JP2012006853A (ja) * | 2010-06-23 | 2012-01-12 | Kansai Univ | メラニン生成抑制剤、化粧剤、皮膚外用剤、医薬部外品および抗癌剤 |
JP2013100267A (ja) * | 2011-10-11 | 2013-05-23 | Daiichi Sankyo Healthcare Co Ltd | ビタミン類を含有する抗炎症のための皮膚外用剤組成物 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3755560A (en) | 1971-06-30 | 1973-08-28 | Dow Chemical Co | Nongreasy cosmetic lotions |
US4421769A (en) | 1981-09-29 | 1983-12-20 | The Procter & Gamble Company | Skin conditioning composition |
ES8503941A1 (es) | 1982-10-27 | 1985-04-16 | Crinos Industria Farmaco | Procedimiento de obtencion de composiciones para promover el trofismo de la piel y de foliculos piliferosos relacionados |
DE3372703D1 (en) | 1982-10-29 | 1987-09-03 | Crinos Industria Farmaco | Cosmetic preparations promoting the trophism of the skin and of the related hair follicles |
JP2593714B2 (ja) | 1989-09-20 | 1997-03-26 | 株式会社 林原生物化学研究所 | 色白剤 |
RU2013088C1 (ru) | 1991-08-09 | 1994-05-30 | Ольга Олеговна Ромашко | Крем для ухода за сухой и нормальной кожей лица и способ его приготовления |
US6238678B1 (en) * | 1995-11-06 | 2001-05-29 | The Procter & Gamble Company | Methods of regulating skin appearance with vitamin B3 compound |
WO1998046206A1 (en) | 1997-04-16 | 1998-10-22 | Peregrine Pharmaceutical, Inc. | Skin cream composition |
JP2000086442A (ja) | 1998-09-17 | 2000-03-28 | Taiyo Kagaku Co Ltd | 美白用皮膚外用剤 |
CZ20012926A3 (cs) * | 1999-02-12 | 2002-02-13 | The Procter & Gamble Company | Kosmetické prostředky obsahující vitaminové B3 sloučeniny |
GB9918023D0 (en) * | 1999-07-30 | 1999-09-29 | Unilever Plc | Skin care composition |
US6555143B2 (en) | 2001-02-28 | 2003-04-29 | Johnson & Johnson Consumer Products, Inc. | Legume products |
GB2381451A (en) | 2001-11-01 | 2003-05-07 | New Technology Res Ltd | Pharmaco-dietary preparation having nutrition-supplementing and nutrition-enhancing effect |
FR2864445B1 (fr) | 2003-12-30 | 2006-04-28 | Jean Noel Thorel | Utilisation topique d'une base nutritive complexe |
US7176172B2 (en) | 2004-10-25 | 2007-02-13 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Quaternary ammonium polyol salts as anti-aging actives in personal care compositions |
US20060088616A1 (en) | 2004-10-26 | 2006-04-27 | Miri Seiberg | Compositions containing malva sylvestris extract and use thereof on mucosal tissues |
FR2877222B1 (fr) | 2004-11-04 | 2008-10-10 | Oreal | Composition cosmetique comprenant un agent hydratant et une hydroxyalkyl uree |
US7776915B2 (en) | 2005-03-24 | 2010-08-17 | Tracie Martyn International, Llc | Topical formulations and methods of use |
BRPI0501569B1 (pt) * | 2005-04-04 | 2015-09-29 | Natura Cosméticos S.A. | Composição cosmética não rinsável na forma de batom ou gloss e produto cosmético que compreende a dita composição |
JP2008540350A (ja) * | 2005-05-03 | 2008-11-20 | ユニリーバー・ナームローゼ・ベンノートシヤープ | 共役リノール酸およびナイアシンアミドを含む美白組成物 |
FR2899103B1 (fr) | 2006-03-28 | 2008-12-12 | Lm Cosmetics Sarl | Utilisation cosmetique de d-ribose |
US20080312169A1 (en) | 2007-03-20 | 2008-12-18 | Clarence Albert Johnson | Cosmetic use of D-ribose |
US9616006B2 (en) * | 2007-10-10 | 2017-04-11 | DermaMedics, LLC | Methods and compositions for treating dermatological diseases and conditions |
DE602007010967D1 (de) | 2007-12-21 | 2011-01-13 | Kosmetische und pharmazeutische Zusammensetzungen | |
GB2472379A (en) | 2009-07-15 | 2011-02-09 | Oskia Skincare Ltd | Topical cosmetic formulation comprising MSM, a vitamin and a carbohydrate |
FR2948286B1 (fr) | 2009-07-27 | 2011-08-26 | Jean-Noel Thorel | Composition injectable associant un agent de comblement et un milieu de croissance des fibroblastes |
KR20130099057A (ko) | 2010-08-19 | 2013-09-05 | 존슨 앤드 존슨 컨수머 캄파니즈, 인코포레이티드 | 셀룰라이트의 치료 방법 |
FR2988292B1 (fr) | 2012-03-23 | 2014-03-21 | Oreal | Composition cosmetique comprenant un compose d'acide cucurbique, un ether de sucre et un polymere acrylique semicristallin |
CN103637952B (zh) | 2013-12-10 | 2015-07-01 | 彭再辉 | 一种美白补水面膜贴用面膜液及其制备方法和应用 |
-
2014
- 2014-10-23 EP EP14792975.6A patent/EP3060311B1/en not_active Not-in-force
- 2014-10-23 JP JP2016522779A patent/JP6507158B2/ja active Active
- 2014-10-23 CA CA2926217A patent/CA2926217C/en active Active
- 2014-10-23 US US14/521,742 patent/US9597271B2/en active Active
- 2014-10-23 CN CN201480058341.2A patent/CN105682748B/zh active Active
- 2014-10-23 WO PCT/US2014/061856 patent/WO2015061512A1/en active Application Filing
- 2014-10-23 KR KR1020167009463A patent/KR101914844B1/ko active IP Right Grant
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040102358A1 (en) * | 1997-05-19 | 2004-05-27 | Scivoletto Rosemarie | Composition for treating skin conditions |
JP2002536390A (ja) * | 1999-02-12 | 2002-10-29 | ザ、プロクター、エンド、ギャンブル、カンパニー | ビタミンb3を含有する化粧品組成物 |
JP2009074061A (ja) * | 2001-05-11 | 2009-04-09 | Penreco | ゲル組成物 |
JP2010513368A (ja) * | 2006-12-22 | 2010-04-30 | ユニリーバー・ナームローゼ・ベンノートシヤープ | 化粧品組成物における単結晶板状硫酸バリウム |
JP2011500597A (ja) * | 2007-10-10 | 2011-01-06 | セラメティックス エルエルシー | 皮膚病又は皮膚病変の治療方法及び組成物 |
JP2011524393A (ja) * | 2008-06-18 | 2011-09-01 | ユニリーバー・ナームローゼ・ベンノートシヤープ | 皮膚の色を美白するための組成物 |
JP2011140489A (ja) * | 2009-12-18 | 2011-07-21 | L'oreal Sa | まつ毛または眉毛メイクアップ組成物 |
JP2012006853A (ja) * | 2010-06-23 | 2012-01-12 | Kansai Univ | メラニン生成抑制剤、化粧剤、皮膚外用剤、医薬部外品および抗癌剤 |
JP2013100267A (ja) * | 2011-10-11 | 2013-05-23 | Daiichi Sankyo Healthcare Co Ltd | ビタミン類を含有する抗炎症のための皮膚外用剤組成物 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018505130A (ja) * | 2016-01-11 | 2018-02-22 | ザ プロクター アンド ギャンブル カンパニー | 皮膚状態を処置する方法及びそのための組成物 |
Also Published As
Publication number | Publication date |
---|---|
CN105682748A (zh) | 2016-06-15 |
US20150118169A1 (en) | 2015-04-30 |
EP3060311A1 (en) | 2016-08-31 |
EP3060311B1 (en) | 2019-05-22 |
CA2926217C (en) | 2018-03-27 |
CN105682748B (zh) | 2021-03-12 |
US9597271B2 (en) | 2017-03-21 |
WO2015061512A1 (en) | 2015-04-30 |
JP6507158B2 (ja) | 2019-04-24 |
KR20160052731A (ko) | 2016-05-12 |
KR101914844B1 (ko) | 2018-11-02 |
CA2926217A1 (en) | 2015-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6507158B2 (ja) | 皮膚を明るくする化粧組成物 | |
ES2421262T3 (es) | Composición para el cuidado personal y cosmética que contiene tetrapéptidos con las unidades CX1X2G, PX1X2P o PX1X2K | |
JP2012516337A (ja) | スキンケア及び/又はヘアケア活性物質を使用した哺乳類ケラチン組織の調整 | |
FR2880802A1 (fr) | Composition cosmetique ou dermopharmaceutique contenant un extrait d'euglene | |
CA2944157C (en) | Cosmetic compositions having reduced irritation | |
JP6389308B1 (ja) | 皮膚外用剤 | |
US20200113800A1 (en) | Cosmetic composition | |
JP2007332066A (ja) | チロシナーゼ産生抑制剤 | |
JP2023538313A (ja) | 天然スキンケア組成物 | |
CN110870880A (zh) | 包含异常毕赤酵母和视黄醇的局部用组合物 | |
US20200215069A1 (en) | Melanin production inhibitor, whitening agent, fibroblast activator, collagen and/or elastin production promotor and wrinkle ameliorant | |
JP4707297B2 (ja) | 外皮用組成物 | |
AU2020405222B2 (en) | Personal care compositions and methods for the same | |
JP2007308516A (ja) | 外皮用組成物 | |
JP5423002B2 (ja) | 亜鉛を有効成分として含有するコラーゲン合成促進剤 | |
JP5520703B2 (ja) | コラーゲン合成促進用組成物 | |
US20230285257A1 (en) | Cosmetic composition | |
JP2004352634A (ja) | 化粧料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20160708 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20160721 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160413 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170323 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170404 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170704 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170904 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171004 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180320 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180620 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180820 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180919 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190305 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190401 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6507158 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |